Early-stage rare disease focus AltiBio, Inc. is a San Francisco Bay Area biopharmaceutical company founded in 2017 with a focus on developing therapeutics for rare and severe diseases, presenting opportunities to align in early-stage partnerships and potential grant-funded research programs.

Limited headcount, outsourcing potential With 0-1 employees, AltiBio is likely to rely on external collaborators and contract research organizations, signaling a strong sales opportunity for CROs, clinical trial services, regulatory affairs consulting, and manufacturing partnerships.

Board expansion activity Recent board appointments (Georgia Erbez and Thomas Smart in Oct 2018) indicate active governance building, suggesting potential engagement through investor relations, strategic advisory services, and partnership discussions tied to their growth milestones.

Milestones and fundraising readiness The company notes ongoing milestones and imminent news, implying readiness for partnerships around two molecules and potential licensing, collaboration agreements, or co-development deals to accelerate development and commercialization.

Financials and market positioning With revenue under one million and competitive context from established biotech firms, there is an opportunity to contextualize value propositions around rare-disease orphan programs, pilot collaborations, and early-access or co-development models that de-risk early-stage investments.